RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
Rhea-AI Summary
RenovoRx (Nasdaq: RNXT) announced acceptance of a clinical data abstract for presentation at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting April 11–15, 2026 in Toronto. The abstract examines PET/CT metabolic response after transarterial microperfusion using the TAMP therapy platform in locally advanced pancreatic cancer.
Presentation is scheduled for April 13, 2026, 4:45–5:45 PM ET (Abstract No. 2229370) and was submitted by a multidisciplinary team including Dr. Mustafa Al-Roubaie of Moffitt Cancer Center.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Two biotech peers in momentum (e.g., BCAB, IPSC) are moving up, but RNXT’s modest 0.9% gain and absence from the momentum list point to a company-specific response rather than a broad sector move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Clinical data presentation | Positive | -4.5% | New TAMP data on intra-arterial pressure measurements at SIO 2026. |
| Jan 28 | Abstract acceptance | Positive | +0.2% | Acceptance of TAMP intravascular pressure abstract at interventional oncology meeting. |
| Jan 08 | Clinical data update | Positive | +13.9% | Phase III TIGeR-PaC sub-study PK/PD data at ASCO GI 2026. |
| Dec 11 | Abstract acceptance | Positive | +1.6% | Acceptance of TIGeR-PaC PK/PD abstract at ASCO GI 2026. |
| Aug 14 | Trial and revenue update | Positive | -22.9% | Q2 2025 revenue growth and positive DMC recommendation for TIGeR-PaC. |
Clinical-trial news has produced mixed reactions, with an average move of -2.35% and both strong rallies and sharp selloffs following updates.
Over the last six months, RenovoRx has repeatedly highlighted its TAMP™ platform and TIGeR-PaC program through clinical-trial disclosures. Events span abstract acceptances at ASCO GI 2026 and interventional oncology meetings, a positive DMC recommendation to continue the pivotal Phase III TIGeR-PaC trial, and detailed PK/PD data showing reduced systemic gemcitabine exposure. These updates, while generally constructive, have led to varied price reactions, framing today’s abstract acceptance as part of an ongoing validation and data-building narrative.
Historical Comparison
In the past 5 clinical‑trial headlines, RNXT’s average move was -2.35%, with both sharp drops and double‑digit gains. This abstract fits the pattern of recurring TAMP and TIGeR‑PaC data milestones.
Clinical updates show progression from interim TIGeR-PaC PK/PD results and DMC review toward broader imaging and delivery optimization data across multiple oncology-focused conferences.
Regulatory & Risk Context
An effective Form S-3 shelf filed on 2025-11-14 allows RNXT to issue up to $50,000,000 of mixed securities over time. The company has already used this shelf once via a 424B5 ATM prospectus, indicating a mechanism is in place for future equity or debt financing to support TIGeR-PaC and RenovoCath commercialization.
Market Pulse Summary
This announcement adds another data point supporting RenovoRx’s TAMP™ platform, focusing on PET/CT metabolic response and intra-arterial chemotherapy in locally advanced pancreatic cancer. It follows a series of clinical-trial abstracts and TIGeR-PaC sub-studies presented at oncology meetings. Investors may watch for how upcoming 2026 conference presentations refine understanding of therapeutic activity and imaging endpoints, while considering the company’s ongoing capital needs under its $50,000,000 shelf and ATM program.
Key Terms
pet/ct medical
transarterial microperfusion medical
intra-arterial medical
intravenous medical
locally advanced pancreatic cancer medical
AI-generated analysis. Not financial advice.
Accepted Abstract Highlights Metabolic Response Observations Following Chemotherapeutic Drug-Delivery via the TAMP™ Therapy Platform in Patients Diagnosed with Locally Advanced Pancreatic Cancer
MOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that a clinical data abstract submission by cancer experts at Moffitt Cancer Center to the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting has been accepted. The meeting will be held April 11-15, 2026, in Toronto, Ontario.
The abstract, titled “What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer,” was submitted by a multidisciplinary team of cancer experts, including Dr. Mustafa Al-Roubaie, an Interventional Radiologist at Moffitt Cancer Center and member of RenovoRx’s Medical Advisory Board. The abstract explores the hypothesis, based on a review of metabolic response observations, that local, targeted intra-arterial delivery of chemotherapy using RenovoRx’s patented TAMP (Trans-Arterial Micro-Perfusion) therapy platform may help address the poor vascularity commonly associated with locally advanced pancreatic cancer (LAPC). The abstract data further evaluates the potential role of metabolic imaging (FDG (fluorodeoxyglucose) PET/CT)) in evaluating therapeutic activity following targeted intra-arterial treatment in patients with refractory disease.
“Patients diagnosed with LAPC carry a difficult prognosis, partly due to a dense, hypovascular stroma that limits the efficacy of traditional systemic (intravenous) chemotherapy,” said Dr. Al-Roubaie. “Regional intra-arterial therapeutic delivery, which is the core attribute of RenovoRx’s TAMP therapy platform, aims to overcome this barrier by delivering high-concentration chemotherapy directly near the tumor. We are excited to present our findings at the upcoming 2026 SIR Meeting.”
Abstract Details:
Presentation Date & Time: Monday, April 13, 2026, from 4:45-5:45 PM ET
Title: What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer
Location: Metro Toronto Convention Centre - Toronto, Canada
Abstract Number: 2229370
About RenovoCath
Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.
About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
RenovoRx is in the initial stages of actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices, and for the first nine months of 2025, approximately
RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
The IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the anticipated benefits to the Company of the clinical data abstract and presentation described herein as well as (i) our clinical trials and studies, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans, or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding-; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate-;(v) that the applicable regulatory authorities may disagree with our interpretation of the data-, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.
Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRx@KCSA.com
FAQ
What will RenovoRx (RNXT) present at the 2026 SIR meeting on April 13, 2026?
Who authored the RNXT abstract accepted to the 2026 SIR Annual Scientific Meeting?
When and where is RenovoRx’s (RNXT) abstract presentation scheduled at SIR 2026?
What clinical question does the RNXT abstract address about pancreatic cancer?
Does the RNXT announcement report final trial results or regulatory decisions?
How might the RNXT TAMP therapy platform be relevant to patients with locally advanced pancreatic cancer?
